| 臺大學術典藏 |
2022-08-19T00:20:34Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; CHIUN HSU; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2022-04-20T08:12:03Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; CHUN-JU CHIANG; Li A.F.-Y.; Wang H.-P.; Wang T.-E.; Bai L.-Y.; Wu M.-S.; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:02Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
|
Su Y.-Y.; Chiu Y.-F.; Li C.-P.; SHIH-HUNG YANG; Lin J.; Lin S.-J.; Chang P.-Y.; Chiang N.-J.; Shan Y.-S.; Ch��ang H.-J.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients�� experience within a population-based study
|
Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-02-14T05:27:14Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; Chiang C.-J.; Li A.F.-Y.; HSIU-PO WANG; Wang T.-E.; Bai L.-Y.; Wu M.-S.; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 臺大學術典藏 |
2022-01-25T07:24:16Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; Chiang C.-J.; Li A.F.-Y.; Wang H.-P.; Wang T.-E.; Bai L.-Y.; MING-SHIANG WU; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 國立成功大學 |
2022 |
Electromagnetically-driven integrated microfluidic platform using reverse transcription loop-mediated isothermal amplification for detection of severe acute respiratory syndrome coronavirus 2
|
Tsai, Y.-S.;Wang, C.-H.;Tsai, H.-P.;Shan, Y.-S.;Lee, G.-B. |
| 國立成功大學 |
2022 |
An integrated microfluidic platform featuring real-time reverse transcription loop-mediated isothermal amplification for detection of COVID-19
|
Jhou, Y.-R.;Wang, C.-H.;Tsai, H.-P.;Shan, Y.-S.;Lee, G.-B. |
